drugset / Trial / NCT02388464

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

NCT02388464

Phase 1 Completed 36 enrolled Stealth BioTherapeutics Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to evaluate the safety, tolerability, and pharmacokinetics of escalating single intravenous infusion doses of Bendavia™ (MTP-131).

Timeline

Start
2014-07
Primary completion
2015-04
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 0.005 mg/kg Intravenous
Subject Elamipretide Peptide 0.05 mg/kg Intravenous
Subject Elamipretide Peptide 0.25 mg/kg Intravenous